Carlos Barrionuevo

Dr. Carlos Barrionuevo

Instituto Nacional de Enfermedades Neoplásicas
+1
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in Blood
Verified
Journal Article
Open access
PDF file
ECElias Campo
Elias Campo
Elaine JaffeElaine Jaffe
Elaine Jaffe
JCJames R. Cook
James R. Cook
LQLeticia Quintanilla-Fend
Leticia Quintanilla-Fend
SSSteven H. Swerdlow
Steven H. Swerdlow
AZAndrew D. Zelenetz
Andrew D. Zelenetz
Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.

24 October 2016 in Current Hematologic Malignancy Reports
Verified
Journal Article
Closed access
PDF file
BHBrad Haverkos
Brad Haverkos
ZPZenggang Pan
Zenggang Pan
AGAlejandro A. Gru
Alejandro A. Gru
AFAharon G. Freud
Aharon G. Freud
RRRachel Rabinovitch
Rachel Rabinovitch
PPPierluigi Porcu
Pierluigi Porcu

1 March 2002 in Applied Immunohistochemistry & Molecular Morphology
Verified
Journal Article
Closed access
Carlos BarrionuevoCarlos Barrionuevo
Carlos Barrionuevo
VAVirginia M. Anderson
Virginia M. Anderson
EZEduardo Zevallos-Giampietri
Eduardo Zevallos-Giampietri
MZMayer Zaharia
Mayer Zaharia
OMOscar Misad
Oscar Misad
Miguel PirisMiguel Piris
Miguel Piris
Hydroa-like cutaneous T-cell lymphoma (hydroa-like CTCL) is an unusual pediatric malignancy with a poor prognosis. An impressive cutaneous rash characterized by edema, blisters, ulcers, crusts, and scars, resembling hidroa vacciniforme, is seen mainly on the face and sometimes on the extremities. The lesion consists of lymphomatous T-cell infiltration of the skin and subcutis with variable exocytosis and angiocentricity. It has been also called edematous, scarring vasculitic panniculitis and hydroa-like lymphoma. An association with Epstein-Barr virus has been suggested. The differential diagnosis includes other cutaneous lymphomas, particularly the cutaneous nasal type T/natural killer–cell lymphoma, mycosis fungoides, precursor T-cell lymphoblastic lymphoma, nonspecific peripheral T-cell lymphoma, cutaneous anaplastic large cell lymphoma, and subcutaneous panniculitic T-cell lymphoma. Other differential diagnoses are inflammatory dermatopathies and panniculitides. Based on a series of 16 such cases referred to the Institute of Neoplastic Diseases, the objective of this report is not only to provide a better clinicopathologic understanding of this entity but also a reappraisal of it as a malignancy. The male/female frequency ratio was 1:1. The median age was 10 years old. All cases showed predominant facial involvement with edema, blisters, ulcers, crusts, and scars. Chemotherapy and/or radiotherapy had little or no benefit. The prognosis was usually dismal. The lymphoma extended from the epidermis to the subcutis, with frequent angiocentric and periadnexal array. Lymphoma cells were mostly of intermediate size with dense hyperchromatic nuclei, inconspicuous nucleoli, and infrequent mitosis. A scanty and variable inflammatory background was found. The lymphoma cells displayed T-cell cytotoxic phenotype. In addition, they were negative for the natural killer cell antigens CD56 and CD57. Epstein-Barr virus in situ hybridization was positive in the six cases in which it was assayed. T-cell receptor γ (TCRγ) displayed monoclonal-type rearrangement in four cases studied. Our findings indicate that hydroa-like CTCL is an independent clinicopathologic entity that affects children Consequently, it should be considered an independent subset of CTCLs and be included as such in the classification of neoplastic diseases of the lymphoid tissues.

1 December 2010 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
SRSocorro Maria Rodr´guez-Pinilla
Socorro Maria Rodr´guez-Pinilla
Carlos BarrionuevoCarlos Barrionuevo
Carlos Barrionuevo
JGJuan Garcia
Juan Garcia
MMMarco T. Mart´nez
Marco T. Mart´nez
RPRaquel Tech. Pajares
Raquel Tech. Pajares
Miguel PirisMiguel Piris
Miguel Piris
We have reviewed clinically, morphologically, and immunophenotypically a series of 14 Epstein-Bar virus (EBV)+ cutaneous natural killer cell (NK)/T-cell lymphoma from Peru. Most (11 out of 14) of these cases fit well into the category of Hydroa vacciniforme-like lymphoma (HVLL), but 3 have a different clinical presentation, without facial involvement. In all 14 cases, skin lesions present in both the sun-exposed and nonexposed areas exhibited a slowly progressive relapsing course, changing from edema, to blistering, ulceration, and final scarring. The immunophenotype had a cytotoxic T or NK-cell lineage. The mean time of disease before admission to hospital was 69 months (range, 6 mo to 31 y). Only 2 patients had fever, hepatosplenomegaly, systemic lymphadenopathy, and a high lactate dehydrodenage (LDH) level at the time of diagnosis, whereas 10 had facial swelling. After treatment, only 4 patients remain alive, although with persistent disease. Ten patients died after a mean follow-up of 11.6 months after the initial diagnosis (range, 1 to 32 mo), because of concurrent infections (4 cases), disease progression (4 patients) or both (2 patients). Endemic Epstein-Bar virus (EBV)-positive cutaneous NK/T-cell lymphoproliferative disorders in childhood and early adulthood are characterized by a protracted clinical course, eventually leading to an aggressive phase characterized by concurrent infections and disease progression.

8 March 2009 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
WRWilson Z. Ray
Wilson Z. Ray
SBSpiros L. Blackburn
Spiros L. Blackburn
SCSandro Casavilca-Zambrano
Sandro Casavilca-Zambrano
Carlos BarrionuevoCarlos Barrionuevo
Carlos Barrionuevo
JOJose E. Orrego
Jose E. Orrego
APArie Perry
Arie Perry

8 October 2015 in Current Hematologic Malignancy Reports
Verified
Journal Article
Closed access
PDF file
AGA. A. Gru
A. A. Gru
BHB. H. Haverkos
B. H. Haverkos
AFA. G. Freud
A. G. Freud
JHJ. Hastings
J. Hastings
NNN. B. Nowacki
N. B. Nowacki
PPPierluigi Porcu
Pierluigi Porcu